Two Sigma Securities LLC Purchases 2,216 Shares of United Therapeutics Corporation $UTHR

Key Points

• Two Sigma Securities increased its United Therapeutics position by 434.5% in the second quarter, buying 2,216 additional shares for a total holding worth approximately $1.48 million. Institutional investors own 94.08% of the company.
• United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year. The stock opened at $510.38, below its 50-day and 200-day moving averages.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $646, although insiders sold 414,075 shares worth roughly $221.6 million during the last quarter, including significant sales by the CEO and CFO.

Two Sigma Securities LLC grew its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 434.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 2,726 shares of the biotechnology company's stock after buying an additional 2,216 shares during the period. Two Sigma Securities LLC's holdings in United Therapeutics were worth $1,477,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in UTHR. Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company's stock worth $127,000 after purchasing an additional 70 shares during the last quarter. Jump Financial LLC bought a new position in shares of United Therapeutics during the second quarter valued at $277,000. Cerity Partners LLC lifted its holdings in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company's stock valued at $3,691,000 after purchasing an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia boosted its position in shares of United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company's stock valued at $468,000 after buying an additional 105 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 1.0%

United Therapeutics stock opened at $510.38 on Tuesday. The business has a 50-day simple moving average of $529.90 and a two-hundred day simple moving average of $539.42. The company has a market cap of $21.89 billion, a P/E ratio of 18.26, a P/E/G ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 52-week low of $303.08 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.41 EPS. Research analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the company's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,311,581.28. This represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm's stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,185,323.93. This represents a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 414,075 shares of company stock worth $221,568,985 over the last quarter. Insiders own 8.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on UTHR. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. raised their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source